The global autoimmune disease therapeutics market size was accounted for nearly $109.92 billion in 2018, and is expected to reach $153.48 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026. The report provides an extensive analysis of key winning strategies, changing market dynamics, market size & projections, and competitive landscape.
Increase in adoption of autoimmune disease therapeutics, surge in wide availability of advanced therapeutics, and rise in number of research and development activities drive the growth in the market. However, high initial costs related to advanced therapeutics restrain the market growth. On the other hand, strong presence of pipeline drugs and opportunities in emerging economies create new pathways in the industry.
Anti-inflammatory segment to maintain its leadership status during the forecast period
Based on drug-class, the anti-inflammatory segment contributed for more than half of the total share in 2017 and is expected to maintain its leadership status during the forecast period. This segment is the fastest growing segment, registering a CAGR of 5.3% from 2018 to 2026. It is a lucrative segment, owing to ease in availability, huge number of target population, and access to advanced drugs. The research also analyzes antihyperglycemics, NSAIDs, interferons, and others.
Rheumatic disease segment to maintain its dominant share by 2026
Based on indication, rheumatic disease segment contributed nearly half of the total market share in 2017 and will maintain its dominant share by 2026. Moreover, this segment would register the highest growth rate, with a CAGR of 5.2% from 2018 to 2026. This is due to increase in prevalence, surge in R&D activities, and availability of advanced therapeutics. The report also analyzes type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others.
Drug stores & retail pharmacies to maintain its dominant position by 2026
Drug stores & retail pharmacies accounted for nearly three-fifths of the total share in 2017 and will maintain its dominant position by 2026, owing to ease in availability offered by them and presence of large number of stores. However, online stores would grow at the fastest rate, registering a CAGR of 6.8% from 2018 to 2026, owing to rise in preference for online channels and advantages such as less expenses, enhanced convenience, and easy access to reviews of other patients.
Leading market players
Leading market players analyzed in the research include Abbott Laboratories, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc., Johnson & Johnson, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, and UCB S.A.
Segmentation:
By Drug Class
Anti-inflammatory
Antihyperglycemics
NSAIDs
Interferons
Others
By Indication
Rheumatic Disease
Type 1 Diabetes
Multiple Sclerosis
Inflammatory Bowel Disease
Other Indications
By Sales Channel
Hospital Pharmacy
Drug Store & Retail Pharmacy
Online Store
The report analyzes and forecasts the autoimmune disease therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global autoimmune disease therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the autoimmune disease therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of autoimmune disease therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Report coverage
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.5. Analyst tools and models
Section 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
Section 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics
3.3.1.2. Increase in incidence of autoimmune disease
3.3.1.3. Wide availability of advanced therapeutics
3.3.2. Restraints
3.3.2.1. Higher cost associated with advanced autoimmune disease therapeutics
3.3.3. Opportunity
3.3.3.1. Growth opportunities in emerging economies
3.3.3.2. Strong presence of pipeline drugs
3.4. Top player positioning, 2017
Section 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Antihyperglycemics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. NSAIDs
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Interferons
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
Section 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatic disease
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country
5.3. Type 1 Diabetes
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country
5.4. Multiple sclerosis
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country
5.5. Inflammatory Bowel Disease
5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast
5.5.3. Market analysis, by country
5.6. Other indications
5.6.1. Key market trends, growth factors, and opportunities
5.6.2. Market size and forecast
5.6.3. Market analysis, by country
Section 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Online providers
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Drug stores & retail pharmacies
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
Section 7: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.1.1. US
7.2.1.1.1. Market size and forecast, by Drug Class
7.2.1.1.2. Market size and forecast, by Indication
7.2.1.1.3. Market size and forecast, by Sales Channel
7.2.1.2. Canada
7.2.1.2.1. Market size and forecast, by Drug Class
7.2.1.2.2. Market size and forecast, by Indication
7.2.1.2.4. Market size and forecast, by Sales Channel
7.2.1.3. Mexico
7.2.1.3.1. Market size and forecast, by Drug Class
7.2.1.3.2. Market size and forecast, by Indication
7.2.1.3.4. Market size and forecast, by Sales Channel
7.2.2. North America Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.2.3. North America Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.2.4. North America Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.2.5. North America Autoimmune Disease Therapeutics Market size and forecast, by region
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.1.1. Germany
7.3.1.1.1. Market size and forecast, by Drug Class
7.3.1.1.2. Market size and forecast, by Indication
7.3.1.1.3. Market size and forecast, by Sales Channel
7.3.1.2. France
7.3.1.2.1. Market size and forecast, by Drug Class
7.3.1.2.2. Market size and forecast, by Indication
7.3.1.2.4. Market size and forecast, by Sales Channel
7.3.1.3. UK
7.3.1.3.1. Market size and forecast, by Drug Class
7.3.1.3.2. Market size and forecast, by Indication
7.3.1.3.4. Market size and forecast, by Sales Channel
7.3.1.4. Italy
7.3.1.4.1. Market size and forecast, by Drug Class
7.3.1.4.2. Market size and forecast, by Indication
7.3.1.4.4. Market size and forecast, by Sales Channel
7.3.1.5. Spain
7.3.1.5.1. Market size and forecast, by Drug Class
7.3.1.5.2. Market size and forecast, by Indication
7.3.1.5.3. Market size and forecast, by Sales Channel
7.3.1.6. Rest of Europe
7.3.1.6.1. Market size and forecast, by Drug Class
7.3.1.6.2. Market size and forecast, by Indication
7.3.1.6.3. Market size and forecast, by Sales Channel
7.3.2. Europe Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.3.3. Europe Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.3.4. Europe Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.3.5. Europe Autoimmune Disease Therapeutics Market size and forecast, by region
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.1.1. Japan
7.4.1.1.1. Market size and forecast, by Drug Class
7.4.1.1.2. Market size and forecast, by Indication
7.4.1.1.4. Market size and forecast, by Sales Channel
7.4.1.2. China
7.4.1.2.1. Market size and forecast, by Drug Class
7.4.1.2.2. Market size and forecast, by Indication
7.4.1.2.3. Market size and forecast, by Sales Channel
7.4.1.3. Australia
7.4.1.3.1. Market size and forecast, by Drug Class
7.4.1.3.2. Market size and forecast, by Indication
7.4.1.3.4. Market size and forecast, by Sales Channel
7.4.1.4. India
7.4.1.4.1. Market size and forecast, by Drug Class
7.4.1.4.2. Market size and forecast, by Indication
7.4.1.4.4. Market size and forecast, by Sales Channel
7.4.1.5. South Korea
7.4.1.5.1. Market size and forecast, by Drug Class
7.4.1.5.2. Market size and forecast, by Indication
7.4.1.5.3. Market size and forecast, by Sales Channel
7.4.1.6. Rest of Asia-Pacific
7.4.1.6.1. Market size and forecast, by Drug Class
7.4.1.6.2. Market size and forecast, by Indication
7.4.1.6.3. Market size and forecast, by Sales Channel
7.4.2. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.4.3. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.4.5. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.4.6. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by region
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.1.1. Brazil
7.5.1.1.1. Market size and forecast, by Drug Class
7.5.1.1.2. Market size and forecast, by Indication
7.5.1.1.4. Market size and forecast, by Sales Channel
7.5.1.2. Saudi Arabia
7.5.1.2.1. Market size and forecast, by Drug Class
7.5.1.2.2. Market size and forecast, by Indication
7.5.1.2.3. Market size and forecast, by Sales Channel
7.5.1.3. South Africa
7.5.1.3.1. Market size and forecast, by Drug Class
7.5.1.3.2. Market size and forecast, by Indication
7.5.1.3.4. Market size and forecast, by Sales Channel
7.5.1.4. Rest of LAMEA
7.5.1.4.1. Market size and forecast, by Drug Class
7.5.1.4.2. Market size and forecast, by Indication
7.5.1.4.3. Market size and forecast, by Sales Channel
7.5.2. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.5.3. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.5.5. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.5.6. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by region
Section 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance
8.2. AbbVie Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Amgen Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. AstraZeneca Plc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance
8.5. Bristol-Myers Squibb Company
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Johnson & Johnson
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. Pfizer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. UCB S.A.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product Portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers